Nutra Pharma (NPHC) Q1 2025 loss deepens, debt in default and going-concern risk
Nutra Pharma Corp. reported higher net sales but a much larger loss for the quarter ended March 31, 2025. Net sales rose to
Nutra Pharma ended the quarter with only
Positive
- None.
Negative
- Going concern uncertainty: The company reports an accumulated deficit of
$77,636,060 , a working capital deficit of$16,296,563 , and explicitly states there is substantial doubt about its ability to continue as a going concern. - Deepening losses: Quarterly net loss widened to
$1,404,923 from$426,934 year over year, driven by higher operating expenses, interest costs, and a$1,007,309 loss from revaluing convertible notes and derivatives. - Highly leveraged, largely current debt: Total debt is
$9,057,034 , with$8,917,698 classified as current and many notes in default or under settlement negotiations, creating significant near-term refinancing and liquidity pressure. - Severe stockholders’ deficit: With total liabilities of
$16,988,016 and assets of$775,179 , stockholders’ deficit stands at$16,212,837 , limiting financial flexibility and making equity financing more challenging. - Adverse legal and regulatory outcomes: A final SEC judgment has led to an accrued legal settlement of
$680,235 , and a separate lawsuit settlement requires$125,000 of payments with a potential$400,000 consent judgment if the payment plan is not met.
Insights
Nutra Pharma shows modest revenue growth but severe leverage, defaults, and going-concern risk.
Nutra Pharma modestly expanded net sales to
The balance sheet is heavily strained: total assets of
Management explicitly notes substantial doubt about continuing as a going concern, citing a working capital deficit of
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
For
the quarterly period ended
| TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT |
For the transition period from _________ to ________
Commission
file numbers
(Name of registrant as specified in its charter)
(State or Other Jurisdiction of Organization) |
(IRS Employer Identification Number) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Ticker symbol(s) | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☐
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S–T (§232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non–accelerated filer, a smaller reporting company, or an emerging growth company.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
Growth Company |
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes ☐ No
As
of March 11, 2026, there were
TABLE OF CONTENTS
| PART I. FINANCIAL INFORMATION | F-1 |
| Item 1. Financial Statements | F-1 |
| Condensed Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024 | F-1 |
| Condensed Consolidated Statements of Operations for the Three months ended March 31, 2025 and 2024 (Unaudited) | F-2 |
| Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the Three months ended March 31, 2025 and 2024 (Unaudited) | F-3 |
| Condensed Consolidated Statements of Cash Flows for the Three months ended March 31, 2025 and 2024 (Unaudited) | F-4 |
| Notes to Condensed Consolidated Financial Statements (Unaudited) | F-5 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 4 |
| Item 3. Quantitative and Qualitative Disclosures about Market Risk | 9 |
| Item 4. Controls and Procedures | 9 |
| PART II. OTHER INFORMATION | 10 |
| Item 1. Legal Proceedings | 10 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 11 |
| Item 3. Defaults Upon Senior Securities | 11 |
| Item 4. Mine Safety Disclosure | 11 |
| Item 5. Other Information | 11 |
| Item 6. Exhibits | 11 |
| 2 |
Nutra Pharma Corp (“Nutra Pharma”) and its wholly owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), are referred to herein as “we”, “our” or “us” (ReceptoPharm is also individually referred to herein).
Forward Looking Statements
This Quarterly Report on Form 10–Q for the period ending March 31, 2025, contains forward–looking statements that involve risks and uncertainties, as well as assumptions that if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward–looking statements. The words or phrases “would be,” “will allow, “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward–looking statements.” We are subject to risks detailed in Item 1(a). All statements other than statements of historical fact are statements that could be deemed forward–looking statements, including: (a) any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; and (b) any statements of the plans, strategies and objectives of management for future operations; and (c) any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward–looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
| 3 |
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
NUTRA PHARMA CORP.
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable | ||||||||
| Accounts receivable - related party, net | ||||||||
| Accounts receivable | ||||||||
| Inventory, current portion | ||||||||
| Other receivables | ||||||||
| Convertible notes receivable, net of discount | ||||||||
| Receivable from sale of Stemsation stocks | ||||||||
| Investment in Stemsation stocks | ||||||||
| Settlement receivables | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Inventory, less current portion | ||||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use assets, net | ||||||||
| Security deposit | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Accrued payroll due to officers | ||||||||
| Due to a related party | - | |||||||
| Accrued interest to related parties | ||||||||
| Due to officers | ||||||||
| Derivative liabilities | ||||||||
| Other debt, net of discount, current portion | ||||||||
| SBA notes payable, current portion | ||||||||
| Operating lease obligations, current portion | ||||||||
| Total current liabilities | ||||||||
| SBA notes payable, less current portion | ||||||||
| Total liabilities | ||||||||
| Commitments and Contingencies (Note 11) | - | |||||||
| Stockholders’ deficit: | ||||||||
| Preferred stock, $ | ||||||||
| Common stock, $ | ||||||||
| Common stock to be issued | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and stockholders’ deficit | $ | $ | ||||||
See the accompanying notes to the unaudited condensed consolidated financial statements
| F-1 |
NUTRA PHARMA CORP.
Condensed Consolidated Statements of Operations
(Unaudited)
| 2025 | 2024 | |||||||
| For the Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Net sales | $ | $ | ||||||
| Net sales to a related party | ||||||||
| Cost of sales | ( | ) | ( | ) | ||||
| Reserve for supplier advances for purchases | ( | ) | ( | ) | ||||
| Gross profit | ||||||||
| Operating expenses: | ||||||||
| Selling, general and administrative | ||||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income (expenses) | ||||||||
| Other income | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Interest expense to related parties | ( | ) | ( | ) | ||||
| Change in fair value of convertible notes and derivatives | ( | ) | ( | ) | ||||
| Gain on settlement of debt and accrued expense | - | |||||||
| Total other expenses, net | ( | ) | ( | ) | ||||
| Loss before income taxes | ( | ) | ( | ) | ||||
| Provision for income taxes | - | - | ||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Net loss per share - basic and diluted | $ | ( | ) | $ | ( | ) | ||
| Weighted average number of shares outstanding during the period - basic | ||||||||
| Weighted average number of shares outstanding during the period - diluted | ||||||||
See the accompanying notes to the unaudited condensed consolidated financial statements
| F-2 |
NUTRA PHARMA CORP.
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
For the Three Months Ended March 31, 2025 and 2024
(Unaudited)
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||||||||
| Preferred Stock | Additional | Total | ||||||||||||||||||||||||||||||||||
| Series B | Common Stock | C.S to be issued | Paid-in | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||||||||
| Balance -December 31, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance -March 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Preferred Stock | Additional | Total | ||||||||||||||||||||||||||||||||||
| Series B | Common Stock | C.S to be issued | Paid-in | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||||||||
| Balance -December 31, 2023 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Common stock issued for debt modification and penalty | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||
| Balance -March 31, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
See the accompanying notes to the unaudited condensed consolidated financial statements
| F-3 |
NUTRA PHARMA CORP.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| 2025 | 2024 | |||||||
| For the Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Change in reserve for supplier advances for purchases | ||||||||
| Net gain on settlement of debt and accrued expense | - | ( | ) | |||||
| Depreciation | ||||||||
| Amortization of convertible notes receivable discount | - | ( | ) | |||||
| Change in fair value of convertible notes and derivatives | ||||||||
| Amortization of loan discount | ||||||||
| Amortization of operating lease right-of-use assets | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| (Increase) decrease in accounts receivable | ( | ) | ||||||
| Increase in accounts receivable - related party, net | ( | ) | - | |||||
| Decrease in inventory | ||||||||
| Increase in other receivables | ( | ) | ( | ) | ||||
| Increase in prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Increase in accounts payable | ||||||||
| Increase in accrued expenses | ||||||||
| Increase in accrued payroll due to officers | ||||||||
| Increase in due to a related party | - | |||||||
| Decrease in deferred revenue - related party | - | ( | ) | |||||
| (Decrease) Increase in accrued interest to related parties | ( | ) | ||||||
| Decrease in operating lease obligations | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | ( | ) | - | |||||
| Net cash used in investing activities | ( | ) | - | |||||
| Cash flows from financing activities: | ||||||||
| Loans from officer | ||||||||
| Repayment of officer loans | ( | ) | ( | ) | ||||
| Proceeds from convertible notes | ||||||||
| Repayment of convertible notes | ( | ) | ( | ) | ||||
| Advances from other notes payable | - | |||||||
| Repayments of other notes payable | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Net change in cash | ( | ) | - | |||||
| Cash - beginning of period | - | |||||||
| Cash - end of period | $ | $ | - | |||||
| Supplemental Cash Flow Information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for income taxes | $ | - | $ | - | ||||
| Non Cash Financing and Investing: | ||||||||
| Common stock issued for debt modification and penalty | $ | - | $ | |||||
| Sale of Stemsation shares for which proceeds were receivable at period end | $ | - | $ | |||||
| Reclassification of convertible notes payable to due to officers | $ | - | $ | |||||
| Reclassification of other receivable to convertible notes receivable | $ | - | $ | |||||
See the accompanying notes to the unaudited condensed consolidated financial statements
| F-4 |
NUTRA PHARMA CORP.
Notes to Unaudited Condensed Consolidated Financial Statements
March 31, 2025
1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization
Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.
Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin®, an over-the-counter pain reliever that is a stronger version of Cobroxin® and is designed to treat severe chronic pain. In December 2014, Nutra Pharma launched Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs. In October 2019, Nutra Pharma launched Equine Pain-Away™, an over-the-counter topical pain reliever designed to treat pain and inflammation in horses. In March 2021, Nutra Pharma launched Luxury Feet™, an over-the-counter pain reliever designed specifically to treat foot pain and inflammation especially for women that wear high heels and stilettos. In October of 2021, Nutra Pharma began manufacturing a zeolite detoxifier called Cell Defender for a third party distributor.
Basis of Presentation and Consolidation
The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K from which the accompanying condensed consolidated balance sheet dated December 31, 2024 was derived.
The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. The results for the interim period presented are not necessarily indicative of the results that may be expected for the full fiscal year.
Liquidity and Going Concern
Our
Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets
and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations,
and have an accumulated deficit of $
There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.
We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. The Company’s common stock is presently on the OTC Market Group’s Expert Market, which means that the Company’s common stock is not eligible for proprietary broker-deal quotes. As this limits our ability to raise capital, our plan is to attempt to secure adequate funding through notes payable until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.
| F-5 |
The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Use of Estimates
The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with U.S. GAAP which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue from Contracts with Customers
The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC Topic 606, revenue recognition has a five-step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.
Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts.
Deferred revenue represents cash received from customers in advance of performance under the contract. Such amounts are recognized as revenue when the related performance obligations are satisfied, which typically occurs upon shipment of the products.
Accounting for Shipping and Handling Costs
We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales.
Accounts Receivable and Allowance for Credit Loss
We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. The Company maintains an allowance for credit losses to reflect the current expected credit losses (“CECL”) over the contractual life of the receivables. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable.
Accounts
receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated
allowances for uncollectible accounts.
| F-6 |
Inventories
Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. We classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of sales. We performed an evaluation of our inventory and related accounts at March 31, 2025 and December 31, 2024, and determined no reserves were necessary.
Financial Instruments
Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.
Cash and cash equivalents
The
Company maintains cash balances in a non-interest-bearing account that currently does not exceed federally insured limits of $
Concentration of Credit Risk
Balances
in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not
hold or issue financial instruments for trading purposes. For the three months ended March 31, 2025 and 2024, sales to Avini Health (“Avini”),
a related party, accounted for approximately
Operating Lease Right-of-Use Asset and Liability
The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), as amended (“ASC Topic 842”). This standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases.
In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2.
Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate.
The Company subleases a portion of its leased facility. Sublease rental income is recorded as a reduction of general and administrative expenses in the condensed consolidated statements of operations, as the amounts are considered a recovery of operating costs rather than revenue from the Company’s primary operations.
| F-7 |
Derivative Financial Instruments
Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to other income. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Convertible Debt
The Company adheres to ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU eliminates certain separation models, including the beneficial conversion feature and cash conversion models, so convertible instruments issued after adoption are generally accounted for as a single liability or equity instrument, unless a conversion feature requires separate derivative accounting under ASC 815. ASU 2020-06 also amends diluted EPS guidance.
The Fair Value Measurement Option
We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging (“ASC Topic 815”). The Company reports interest expense, including accrued interest, related to this convertible debt under the fair value option, within the change in fair value of convertible notes and derivatives in the accompanying condensed consolidated statements of operations.
Derivative Accounting for Convertible Debt and Options and Warrants
The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging. The conversion terms of some of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the debt is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debt are included in the value of the derivative liabilities. Pursuant to ASC 815-15, Embedded Derivatives, the fair values of the convertible debt, options and warrants and shares to be issued were recorded as derivative liabilities on the issuance date and revalued at each reporting period.
Debt Modifications and Extinguishments
The Company evaluates amendments, restatements, or other changes to its debt agreements in accordance with ASC 470-50, Debt — Modifications and Extinguishments. Under this guidance, we determine whether the revised terms represent a modification of the existing debt or an extinguishment of the old debt and issuance of new debt. If the changes are not deemed substantial, the transaction is accounted for as a modification and any associated fees or costs are amortized over the remaining term of the modified debt. If the changes are determined to be substantial, the original debt is considered extinguished, the new debt is recorded at fair value, and any resulting difference between the carrying amount of the old debt and the fair value of the new debt is recognized in earnings as a gain or loss on extinguishment.
| F-8 |
Property and Equipment
Property
and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements,
maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over
the estimated useful lives of the assets of
Long-Lived Assets
The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.
Income Taxes
The Company recorded no income tax expense for the three months ended March 31, 2025 and 2024 because the estimated annual effective tax rate was zero. The Company applies the asset and liability method of accounting for income taxes, under which deferred tax assets and liabilities are recognized for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities, as well as for net operating loss and tax credit carryforwards. Deferred tax assets are reduced by a valuation allowance when, based on available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
As of March 31, 2025 and December 31, 2024, the Company continues to maintain a full valuation allowance against its net deferred tax assets due to a history of operating losses and the uncertainty regarding the Company’s ability to generate sufficient future taxable income to realize such assets. The Company’s federal and state income tax returns for 2021 to 2024 have not yet been filed as of March 31, 2025.
Stock-Based Compensation
We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation (“ASC Topic 718”) which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.
Net Income (Loss) Per Share
Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share. Basic income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of conversion options would come from newly issued common shares from our remaining authorized shares.
| F-9 |
The following table summarizes the weighted average securities that were excluded from the diluted per share calculation because for the three months ended March 31, 2025 and 2024, the effect of including these potential shares was antidilutive due to a net loss:
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE
| March 31, 2025 | March 31, 2024 | |||||||
| Convertible notes payable at fair value | ||||||||
| Convertible notes payable | ||||||||
| Total | ||||||||
Segment Reporting
The Company adheres to ASU No. 2023-07, Codification Improvements to Segment Reporting (Topic 280) (“ASU 2023-07”), which provides clarifications and improvements to the existing segment reporting requirements, including updates related to the aggregation criteria, reconciliation of segment measures to condensed consolidated financial statements, and disclosure requirements.
Recent Accounting Pronouncements
Adopted Pronouncements
Effective January 1, 2025, the Company adopted ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740) (“ASU 2023-09”), which enhances the existing income tax disclosure requirements by requiring greater disaggregation within the effective tax rate reconciliation and expanded information regarding income taxes paid by jurisdiction. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The adoption of this ASU did not have a material effect on the accompanying condensed consolidated financial statements.
Not Yet Effective Pronouncements
The Company has evaluated the impact of the following recently issued accounting standards, which have not yet been adopted as of March 31, 2025:
ASU No. 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20): Accounting for Convertible Debt Instruments (“ASU 2024-04”), amends existing guidance to clarify and refine the recognition, measurement, presentation, and disclosure requirements for certain convertible debt arrangements, including matters related to classification, embedded features, and related disclosures. The amendments are intended to improve consistency and comparability in the accounting for convertible debt instruments. This guidance is effective for the Company beginning January 1, 2026. The Company is in the process of evaluating the impact of adopting this standard on its condensed consolidated financial statements.
ASU No. 2025-05, Financial Instruments—Credit Losses (Topic 326): Improvements to Credit Loss Guidance (“ASU 2025-05”), amends the existing guidance under the current expected credit losses (“CECL”) model to clarify and refine the requirements related to the measurement, presentation, and disclosure of credit losses for financial assets measured at amortized cost. This guidance is effective for the Company beginning January 1, 2026. The Company is in the process of evaluating the impact of adopting this standard on its condensed consolidated financial statements.
All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.
2. FAIR VALUE MEASUREMENTS
Certain assets and liabilities that are measured at fair value on a recurring basis at March 31, 2025 and December 31, 2024 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the condensed consolidated financial statements.
The statement requires fair value measurement be classified and disclosed in one of the following three categories:
| Level 1: | Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; |
| Level 2: | Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and |
| Level 3: | Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). |
| F-10 |
The following table summarizes our financial instruments measured at fair value at March 31, 2025 and December 31, 2024:
SCHEDULE OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Fair Value Measurements at March 31, 2025 | ||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Liabilities: | ||||||||||||||||
| Derivative liabilities | $ | $ | - | $ | $ | - | ||||||||||
| Convertible notes at fair value | $ | $ | - | $ | - | $ | ||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Fair Value Measurements at December 31, 2024 | ||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||
| Liabilities: | ||||||||||||||||
| Derivative liabilities | $ | $ | - | $ | $ | - | ||||||||||
| Convertible notes at fair value | $ | $ | - | $ | - | $ | ||||||||||
We valued derivative liabilities using the number of potential convertible shares for convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at March 31, 2025. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt should be accounted for as liabilities.
The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at March 31, 2025 and December 31, 2024:
SCHEDULE OF ASSUMPTIONS AND THE SIGNIFICANT TERMS
Conversion Price - Lower of Fixed VWAP for Look-back Period | ||||||||||||||||
| Debenture | Face Amount | Interest Rate | Default Interest Rate | Discount Rate | Anti-Dilution Adjusted Price | % of stock price for look-back period | Look-back Period | |||||||||
| March 31, 2025 | $ | N/A | $ | |||||||||||||
| December 31, 2024 | $ | N/A | $ | |||||||||||||
| F-11 |
Using the stated assumptions summarized in the table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the three months ended March 31, 2025 and the year ended December 31, 2024:
SCHEDULE OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS
| Description | March 31, 2025 | December 31, 2024 | ||||||
| Beginning balance | $ | $ | ||||||
| Loss from change in fair value (1) | ||||||||
| Ending balance | $ | $ | ||||||
| (1) |
3. INVENTORIES
Inventories are valued at the lower of cost or net realizable value on an average cost basis. At March 31, 2025 and December 31, 2024, inventories were as follows:
SCHEDULE OF INVENTORIES
| March 31, 2025 | December 31, 2024 | |||||||
| Raw Materials | $ | $ | ||||||
| Finished Goods | ||||||||
| Total Inventories | ||||||||
| Less: Long-term inventory | ( | ) | ( | ) | ||||
| Current portion | $ | $ | ||||||
4. PROPERTY AND EQUIPMENT
Property and equipment consists of the following at March 31, 2025 and December 31, 2024:
SCHEDULE OF PROPERTY AND EQUIPMENT
| March
31, 2025 |
December
31, 2024 |
|||||||
| Furniture and fixtures | $ | $ | ||||||
| Lab equipment | ||||||||
| Total | ||||||||
| Less: Accumulated depreciation | ( |
) | ( |
) | ||||
| Property and equipment, net | $ | $ | ||||||
We
review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At March 31,
2025, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the three-months ended March
31, 2025 and 2024 was $
| F-12 |
5. DUE TO/FROM OFFICERS
At
March 31, 2025 and December 31, 2024, the balance due to Rik Deitsch, the Company’s former CEO, and the companies majority owned
and controlled by him (collectively referred to as “Due to Officer”) in the aggregate is $
During
the three months ended March 31, 2025, in the aggregate, we repaid $
Interest
expense related to amounts due to the officer was $
During
March 2024, upon the appointment of Michael Flax as the Company’s Chief Executive Officer, the Company reclassified convertible
notes payable totaling $
These transactions were not conducted on an arm’s-length basis and, as such, may differ from the terms that would have been negotiated with an unrelated third party.
6. DEBTS
Debts consist of the following at March 31, 2025 and December 31, 2024:
SCHEDULE OF DEBT
| March 31, 2025 | December 31, 2024 | |||||||
| Notes payable – Unrelated third parties (Net of discount of $ | $ | $ | ||||||
| Convertible notes payable – Unrelated third parties (Net of discount of $ | ||||||||
| Convertible notes payable, at fair value (3) | ||||||||
| Other advances from an unrelated third party (4) | ||||||||
| SBA notes payable (5) | ||||||||
| Ending balances | ||||||||
| Less: Long-term portion- SBA notes payable | ( | ) | ( | ) | ||||
| Current portion | $ | $ | ||||||
| (1) |
| ● | In
August 2016, we issued two Promissory Notes for a total of $ |
| F-13 |
| ● | On
August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total
of $ | |
| ● | At
December 31, 2012, we owed University Centre West Ltd. approximately $ | |
| ● | In
April 2016, we issued a promissory note to an unrelated third party in the amount of $ | |
| ● | In
May 2016, the Company issued a promissory note to an unrelated third party in the amount of $ | |
| ● | In
June 2016, the Company issued a promissory note to an unrelated third party in the amount of $ | |
| ● | A
promissory note originally issued to an unrelated third party in August 2016 was restated in September 2019 in the amount of $ | |
| ● | On
September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $ |
| F-14 |
| ● | In
October 2016, we issued a promissory note to an unrelated third party in the amount of $ | |
| ● | In
June 2017, we issued a promissory note to an unrelated third party in the amount of $ | |
| ● | During
July 2017, we received a loan for a total of $ | |
| ● | In
July 2017, we issued a promissory note to an unrelated third party in the amount of $ | |
| ● | In
November 2017, we issued a promissory note to an unrelated third party in the amount of $ | |
| ● | In
November 2017, we issued a promissory note to an unrelated third party in the amount of $ |
| F-15 |
| ● | In
October 2024, the Company entered into a Purchase and Sale of Future Receipts Agreement with a third party. Pursuant to this agreement,
the buyer purchased $ | |
| ● | On
December 6, 2024, the Company received a $ | |
| ● | On
December 31, 2024, the Company entered into a Purchase and Sale of Future Receipts Agreement with a third party. Pursuant to this
agreement, the buyer purchased $ |
| (2) |
| ● | In
October 2017, we issued a promissory note to an unrelated third party in the amount of $ | |
| ● | During
January through December 2018, we issued convertible notes payable to 14 unrelated third parties for a total of $ | |
| ● | During
February 2019, the Company issued convertible notes payable totaling $ |
| ● | During
November 2019, we issued a convertible promissory note to an unrelated third party for $ | |
| At
March 31, 2025 and December 31, 2024, the outstanding principal balance of the notes issued in 2019 was $ | ||
| ● | During
the year ended December 31, 2020, the Company issued convertible notes payable of $ | |
| ● | During
2021, we issued convertible promissory notes to unrelated third parties totaling $ |
| F-16 |
| ● | During
August 2021,a promissory note of $
Amortization
of debt discount for the three months ended March 31, 2025 and 2024 was $
In
February 2026, the note was further restated, with the principal balance of $ |
| ● | During
2022, we issued convertible promissory notes to unrelated third parties totaling $ | |
| ● | During
2022, convertible promissory notes totaling $ | |
| ● | During
2022, the Company settled a total of $ | |
| ● | In
February and November 2023, the Company settled two convertible notes which had a conversion price of $ |
| ● | During
the third quarter of 2023, the Company settled convertible promissory notes of $ | |
| ● | During
2023, the Company amended convertible promissory notes totaling $ | |
| ● | During
2023, the Company issued convertible promissory notes to unrelated third parties with a fixed conversion price of $ |
| F-17 |
| ● | During
2024, a convertible promissory note of $ | |
| ● | During
2024, the Company issued convertible promissory notes to unrelated third parties with fixed conversion prices ranging from $ | |
| ● | During
the second quarter of 2024, the Company settled convertible promissory notes with an aggregate principal balance of $ | |
| ● | During
the third quarter of 2024, the Company settled convertible promissory notes of $ | |
| ● | During
the first quarter of 2025, the Company issued convertible promissory notes to unrelated third parties for $ | |
| ● | The
total discount amortization on all notes for the three months ended March 31, 2025 and 2024 was $ | |
| ● | At
March 31, 2025, $ |
| (3) |
| ● | The
balance of $ | |
| ● | During
May 2017, we issued a Convertible Debenture in the amount of $ | |
| ● | During
October 2020, we issued a Convertible Debenture in the amount of $ |
| F-18 |
| ● | During
July 2018, we issued a convertible debenture in the amount of $ | |
| ● | During
January 2019, we issued a convertible debenture in the amount of $ | |
| ● | During
June 2019, we issued a convertible promissory note to an unrelated third party for $ |
| (4) | |
| (5) |
At March 31, 2025, the future minimum principal payments for all debts are as follows:
SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT
| March 31, | Amount | |||
| 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Thereafter | ||||
| Total | $ | |||
| Less: Long-term portion SBA notes payable | ( | ) | ||
| Current portion | $ | |||
| F-19 |
7. STOCKHOLDERS’ DEFICIT
Series B Preferred Stock
Effective
March 2021, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination for its Series B Preferred
Stock. The Series B Preferred Stock has a par value of $
Terms of the Series B Preferred include the following:
| 1. | The Series B Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series B Preferred is entitled to one thousand votes per share. | |
| 2. | The Series B Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series B Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series B Preferred will have the same record and payment date and terms as the dividend payable on the common stock. | |
| 3. | Upon
any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series B Preferred
then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an
amount in cash equal to $ | |
| 4. | The Series B Preferred does not have any redemption rights. |
During
November 2021, the Board of Directors approved resolutions for the issuance of a total of
Effective
November 15, 2021, the Board of Directors authorized an exchange of
8. ACCRUED EXPENSES
Accrued expenses consisted of the following:
SCHEDULE OF ACCRUED EXPENSES
March 31, 2025 | December 31, 2024 | |||||||
| Accrued consulting fees | $ | $ | ||||||
| Accrued settlement expenses (1) | ||||||||
| Accrued payroll taxes | ||||||||
| Accrued interest | ||||||||
| Accrued others | ||||||||
| Total | $ | $ | ||||||
| (1) |
| F-20 |
9. PREPAID EXPENSES
Prepaid expenses and other current assets consist of the following:
SCHEDULE OF PREPAID EXPENSES
March 31, 2025 |
December
31, 2024 |
|||||||
| Supplier advances for venom | $ | $ | ||||||
| Reserve for supplier advances | ( |
) | ( |
) | ||||
| Net supplier advances | - | - | ||||||
| Prepaid professional fees | ||||||||
| Total | $ | $ | ||||||
We
performed an evaluation of our supplier advances for venom at March 31, 2025 and December 31, 2024, and determined full reserves were
necessary. The Company recorded increases to the reserve of $
10. CONVERTIBLE NOTES RECEIVABLE
During
2021 through 2023, we purchased an aggregate of $
On
June 5, 2023, the Company entered into a settlement agreement with StemSation to convert the notes receivable balances of $
Pursuant
to the agreement, the Company is entitled to receive
Between
July and November 2023, $
SCHEDULE OF CONVERTIBLE SETTLEMENT OF DEBT
| Date of Conversion Notice | Conversion Amount | Number of Shares Issued | Value of Shares Issued | |||||||||
| 7/12/2023 | $ | |||||||||||
| 8/24/2023 | $ | |||||||||||
| 11/7/2023 | $ | |||||||||||
Of
the
In
March 2024, the Company sold an additional
During
the third and fourth quarter of 2023, we purchased three convertible notes for $
Convertible
notes receivable were $
| F-21 |
11. COMMITMENTS AND CONTINGENCIES
Operating Leases
SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION
| March 31, | March 31, | |||||||
| 2025 | 2024 | |||||||
| Lease cost | ||||||||
| Operating lease cost | $ | $ | ||||||
| Short-term lease cost | - | - | ||||||
| Total lease cost | $ | $ | ||||||
| Supplemental cash flow information related to leases were as follows: | ||||||||
| Cash paid for amounts included in the measurement of operating lease liabilities | $ | $ |
| |||||
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Balance sheet information | ||||||||
| Operating ROU Assets | $ | $ | ||||||
| Less accumulated amortization | ( | ) | ( | ) | ||||
| Operating ROU Assets, net | $ | $ | ||||||
| Operating lease obligations, current portion | $ | $ | ||||||
| Operating lease obligations, non-current portion | - | - | ||||||
| Total operating lease obligations | $ | $ | ||||||
| Weighted average remaining lease term (in years) – operating leases | ||||||||
| Weighted average discount rate-operating leases | % | % | ||||||
The
Company subleases a portion of its leased facility under month-to-month arrangements. Sublease rental income is recorded as a reduction
of general and administrative expenses in the condensed consolidated statements of operations, as the amounts represent recoveries of
operating costs rather than revenues from the Company’s primary business activities. The sublease arrangements are short-term and
operate on a month-to-month basis. Total sublease rental income was $
Consulting Agreements
During
July 2015, we signed an agreement with a company to provide consulting services for
During
October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement,
During
September 2022, the Company renewed its consulting agreement with an external consultant for a three-year term, providing for monthly
compensation of $
On
January 1, 2025, the Company entered into an Agent and Representation Agreement with an external consulting company pursuant to which
the agent will solicit prospective commercial and contract manufacturing clients on behalf of the Company. Under the agreement, the Company
is obligated to pay referral commissions to the agent for clients introduced by the agent who purchase the Company’s products or
services. The agreement required an initial payment of $
| F-22 |
Litigation
CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150
On
October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida
(Case No. CACE 18-023150) to recover $
Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus
On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws.
On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On June 30, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021.
In
July 2024, a final judgment was issued, ordering the defendant to pay $
Settlement Discussions
Subsequent to year end, the Company entered into a settlement agreement with a counterparty in connection with a dispute arising in the ordinary course of business (See Note 15).
| F-23 |
12. SEGMENT AND ENTITY-WIDE INFORMATION
The Company operates as a single reportable operating segment. Operating segments are identified based on the manner in which the Company’s Chief Operating Decision Maker (“CODM”), who is the Company’s Chief Executive Officer, reviews financial information for purposes of allocating resources and assessing performance.
The CODM reviews financial results and manages the business on a consolidated basis, without differentiation by product line, geographic region, or legal entity. Accordingly, the Company has determined that it has one operating and one reportable segment.
The measure of segment profit or loss used by the CODM is consolidated net loss, as reported in the condensed consolidated statements of operations. The significant expense categories included in the measure of segment profit or loss and regularly reviewed by the CODM include cost of goods sold, selling and marketing expenses, and general and administrative expenses.
The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies. The Company has no intersegment revenues.
For the three months ended March 31, 2025 and 2024, sales to a related party, accounted for approximately 33% and 48% of total revenues, respectively. These sales are included within the Company’s single reportable operating segment. See Note 13 – Related Party Transactions for additional information.
13. RELATED PARTY TRANSACTIONS
The Company acts as a product formulator and contract manufacturer for Avini Health (“Avini”). The Company’s former chief executive officer, who held that position through March 2024, is an owner of Avini and is its chief scientific officer. Following March 2024, this individual assumed the role of Operations Manager of the Company.
During September 2023, the sales and manufacturing structure between the Company and Avini was revised. Avini assumed responsibility for manufacturing its own products, and the Company transferred to Avini certain raw materials and packaging supplies related to amounts previously advanced by Avini. In connection with this transition, the Company relocated its operations to a Boca Raton facility leased by Avini. Under this arrangement, the Company uses the facility rent-free, shares space and resources with Avini, and Avini pays all lease and office-related expenses. Sales to Avini declined beginning in 2024 as Avini manufactures its own products; however, the Company benefits from reduced operating costs and continued access to manufacturing capabilities for its own Nutra Pharma–branded products.
As
of December 31, 2024, the Company had recorded deferred revenue of $
As
of March 31, 2025 and December 31, 2024, the Company recorded accounts receivable from related party of $
During
early 2025, Avini purchased certain raw materials on behalf of the Company for use in the manufacture of private label products. As of
March 31, 2025, $
| F-24 |
During
the first quarter of 2024, the Company reclassified a portion of previously issued convertible debts for a total of $
During
2010 we borrowed $
As of March 31, 2025 and December 31, 2024, we had the following related party balances:
SCHEDULE OF RELATED PARTY BALANCES
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Account receivable – related party, net | $ | $ | ||||||
| Due to a related party | - | |||||||
| Due to officers (See Note 5) | ||||||||
| Accrued payroll due to officers | ||||||||
| Accrued interest to a related party | ||||||||
| Additional paid in capital – related party debt forgiveness | - | |||||||
For the three months ended March 31, 2025 and 2024, we had the following related party transactions:
SCHEDULE OF RELATED PARTY TRANSACTIONS
March 31, 2025 |
March 31, 2024 |
|||||||
| Net sales to a related party | $ | $ | ||||||
| Raw materials purchased from a related party | - | |||||||
| Interest expense to a related party | ||||||||
These transactions were not conducted at arm’s length and therefore may not reflect the terms that would have been agreed to with an unrelated third party.
14. RESEARCH SERVICES AGREEMENT WITH STEMSATION
On
July 1, 2024, the Company entered into a one-year Research Services Agreement with StemSation to provide research and development services
related to certain StemSation technologies. Under the agreement, the Company was entitled to receive $
15. SUBSEQUENT EVENTS
Convertible Promissory Notes
During
April through August 2025, an aggregate of $
| F-25 |
During
April and May 2025, we issued convertible promissory notes to unrelated third parties for a total of $
During
September to November 2025, we issued convertible promissory notes to unrelated third parties for a total of $
Promissory Notes
In
September 2025, the Company entered into a Purchase and Sale of Future Receipts Agreement with a third party. Pursuant to this agreement,
the buyer purchased $
Settlement of Promissory Note Litigation
On
May 19, 2025, the Company entered into a settlement agreement with the counterparty, under which the total obligation was resolved for
$
Restatements of One Convertible Promissory Note
In
February 2026, a convertible promissory note of $
Debt Settlement and Stock Issuance
In
January 2026, the Company entered into a settlement agreement with the holder of certain promissory notes originally issued in 2021 and
2022. As of the settlement date, the aggregate carrying value of the outstanding debt was approximately $
Consulting agreement and Stock Issuance
On
May 1, 2025, the Company entered into a consulting agreement for services. Under the agreement, the Company agreed to issue up to
| F-26 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Introduction
Our business during the three months ended March 31, 2025 has focused upon marketing our homeopathic drugs for the treatment of pain:
| ● | Nyloxin (Stage 2 Pain) | |
| ● | Nyloxin Extra Strength (Stage 3 Pain) | |
| ● | Pet Pain–Away | |
| ● | Equine Pain–Away | |
| ● | Luxury Feet |
During the three months ended March 31, 2025 and thereafter, the following has occurred:
We are currently expanding production capacity in our facility to allow spot production of our products and private label brands.
Nyloxin/Nyloxin Extra Strength
We offer Nyloxin/Nyloxin Extra Strength as our over-the-counter (OTC) pain reliever that has been clinically proven to treat moderate to severe (Stage 2) chronic pain.
Nyloxin and Nyloxin Extra Strength are available as a two-ounce topical gel for treating joint pain and pain associated with arthritis and repetitive stress, and as a one ounce oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain. Both the topical gel and oral spray are packaged and sold as a one-month supply.
Nyloxin and Nyloxin Extra Strength offer several benefits as a pain reliever. With increasing concern about consumers using opioid and acetaminophen-based pain relievers, the Nyloxin products provide an alternative that does not rely on opiates or non-steroidal anti-inflammatory drugs, otherwise known as NSAIDs, for their pain-relieving effects. Nyloxin also has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API) of Nyloxin, Asian cobra venom, has been studied in more than 46 human clinical studies. The data from these studies provide clinical evidence that cobra venom provides an effective treatment for pain with few side effects and has the following benefits:
| ● | safe and effective; | |
| ● | all natural; | |
| ● | long-acting; | |
| ● | easy to use; | |
| ● | non-narcotic; | |
| ● | non-addictive; and | |
| ● | analgesic and anti-inflammatory. |
Potential side effects from the use of Nyloxin are rare, but may include headache, nausea, vomiting, sore throat, allergic rhinitis and coughing.
The primary difference between Nyloxin and Nyloxin Extra Strength is the dilution level of the venom. The approximate dilution levels for Nyloxin and Nyloxin Extra Strength are as follows:
Nyloxin
| ● | Topical Gel: 30 mcg/mL | |
| ● | Oral Spray: 70 mcg/mL |
Nyloxin Extra Strength
| ● | Topical Gel: 60 mcg/mL | |
| ● | Oral Spray: 140 mcg/mL |
In December 2011, we began marketing Nyloxin and Nyloxin Extra Strength at www.nyloxin.com. Both Nyloxin and Nyloxin Extra Strength are packaged in a roll-on container, squeeze bottle and as an oral spray. Additionally, Nyloxin topical gel is available in an 8 ounce pump bottle.
We are currently marketing Nyloxin and Nyloxin Extra Strength as treatments for moderate to severe chronic pain. Nyloxin is available as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress. Nyloxin Extra Strength is available as an oral spray and gel application for treating the same physical indications but is aimed at treating the most severe (Stage 3) pain that inhibits one’s ability to function fully.
The Nyloxin products are available for sale on the www.Nyloxin.com website, the Nyloxin Amazon storefront at www.Amazon.com/nyloxin and on the Walmart Marketplace. Nyloxin is also sold in physician offices, clinics and small-chain pharmacies.
| 4 |
Nyloxin Military Strength
In December 2012, we announced the availability of Nyloxin Military Strength for sale to the United States Military and Veteran’s Administration. Over the past few years, the U.S. Department of Defense has been reporting an increase in the use and abuse of prescription medications, particularly opiates. In 2009, close to 3.8 million prescriptions for pain relievers were written in the military. This staggering number was more than a 400% increase from the number of prescriptions written in the military in 2001. But prescription drugs are not the only issue. The most common and seemingly harmless way to treat pain is with non–steroidal, anti–inflammatory drugs (NSAIDS). But there are risks. Overuse can cause nausea, vomiting, diarrhea, heartburn, ulcers and internal bleeding. In severe cases chest pain, heart failure, kidney dysfunction and life–threatening allergic reactions can occur. It is reported that approximately 7,600 people in America die from NSAID use and some 78,000 are hospitalized. Ibuprofen, also an NSAID has been of particular concern in the military. The terms “Ranger Candy” and “Military Candy” refer to the service men and women who are said to use 800mg doses of Ibuprofen to control their pain. But when taking anti–inflammatory Ibuprofen in high doses for chronic pain, there is potential for critical health risks; abuse can lead to serious stomach problems, internal bleeding and even kidney failure. There are significantly greater health risks when abuse of this drug is combined with alcohol intake. Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military. The Nyloxin Military Strength represents the strongest version of Nyloxin available and is approximately twice as strong as Nyloxin Extra Strength. We are working with outside consultants to register Nyloxin Military Strength and the other Nyloxin products for sale to the US government and the various arms of the military as well as the Veteran’s Administration. In February of 2018, Nyloxin was added to the Federal Supply Schedule but was subsequently removed the following week without an adequate explanation. We have continued to work with our consultants to understand why our products were improperly removed the Federal Supply Schedule and when we may be able to get re-listed on the Federal Supply Schedule for eventual sales to governmental agencies or to the US Military.
International Sales
We are pursuing international drug registrations in Canada, Mexico, India, Australia, New Zealand, Central and South America and Europe. Since European rules for homeopathic drugs are different than the rules in the US, we cannot estimate when this process will be completed. On March 25, 2013 we announced the publication of our patent and trademark for Nyloxin in India. We are actively seeking new distribution partners in India.
On May 14, 2015 we announced that we had engaged the Nature’s Clinic to begin the process of regulatory approval of our Company’s Over–the–Counter pain drug, Nyloxin for marketing and distribution in Canada. The Nature’s Clinic has already begun setting up their Chatham, Ontario warehouse. Due to lack of funding and then the subsequent COVID crisis, we have waited to complete the approval process to begin distributing Nyloxin and expect to re-engage in the process in 2026.
Additionally, we plan to complete several human clinical studies aimed at comparing the ability of Nyloxin Extra Strength to replace prescription pain relievers. We have provided protocols to several hospitals and will provide details and timelines when those protocols have been accepted. We cannot provide any timeline for these studies until adequate financing is available.
To date, our marketing efforts have been limited due to lack of funding. As sales increase, we plan to begin marketing more aggressively to increase the sales and awareness of our products.
Pet Pain–Away
During June of 2013, we announced the launch of our new homeopathic formula for the treatment of chronic pain in companion animals, Pet Pain–Away. Pet Pain–Away is a homeopathic, non–narcotic, non–addictive, over–the–counter pain reliever, primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats. The initial product run was completed in December of 2014 and launched through Lumaxa Distributors on December 19, 2014.
In May of 2016, we signed a license agreement to begin the process of creating an infomercial (Direct Response) campaign for Pet Pain–Away. In November of 2016, we announced the license agreement with DEG Productions for the marketing and distribution of Pet Pain–Away globally. DEG created their own website (www.getpetpainaway.com) and began airing commercials in December of 2016.
In February of 2020, we took back the marketing of Pet Pain-Away and are currently selling the product on Amazon.com, Chewy.com, and www.petpainaway.com.
| 5 |
Luxury Feet
In June of 2017, we announced the creation of Luxury Feet; an over–the–counter pain reliever and anti–inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos. We announced the official marketing launch of Luxury Feet in March of 2021. The product is currently available through www.luxuryfeet.com and on Amazon.
Equine Pain-Away (Formerly Equine Nyloxin)
In October of 2013, we announced that we were in the process of launching the newest addition to our line of homeopathic treatments for chronic pain, Equine Nyloxin. We had been working with trainers and veterinarians in the equine industry and have already identified distributors for the product. The Equine Nyloxin represents the Company’s first topical solution for the animal market. Equine Nyloxin was rebranded as Equine Pain-Away™ and officially rolled into the market in October of 2019. Equine Pain-Away is being marketed through several retailers and online at www.EquinePainAway.com and on Amazon.
Drug Discovery and Pipeline
Nutra Pharma is developing proprietary therapeutic protein products for the biologics market. The Company has two leading drug candidates: RPI–MN and RPI–78M.
RPI–MN
RPI–MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and Human Immunodeficiency Virus (HIV). It is being developed first for the treatment of HIV.
RPI–78M
RPI–78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological and autoimmune disorders that may be served by RPI–78M include Myasthenia Gravis (MG), Rheumatoid Arthritis (RA) and Amyotrophic Lateral Sclerosis (ALS).
RPI–78M and RPI–MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to Nutra Pharma, the drugs are created through a process of chemical modification.
In September, 2015 RPI–78M was granted Orphan Status by the FDA for the treatment of pediatric Multiple Sclerosis. This allows for much shorter timelines to drug approval, waiver of FDA fees (around $2.5M), rolling review and fast–track approval. Orphan status also allows for potential grant money and other funding opportunities through the clinical process.
RPI–MN and RPI–78M possess several desirable properties as drugs:
● They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
● They display no serious adverse side effects following years of investigations in humans and animals.
● They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs’ stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
● RPI–78M may be administered orally –– a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.
● They are easy to administer.
We are currently working with consultants to develop trial protocols for a Phase I/II trial for the use of RPI–78M in the treatment of Pediatric Multiple Sclerosis. Our goal is to initiate these trials in 2026.
| 6 |
Critical Accounting Policies and Estimates
Our condensed consolidated unaudited financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) applied on a consistent basis. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Our critical accounting policies and estimates are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K filed with the SEC on February 17, 2026. We evaluated the applicability of ASU No. 2023-07, Codification Improvements to Segment Reporting (Topic 280) (“ASU 2023-07”), which provides clarifications and improvements to the existing segment reporting requirements. The adoption resulted in expanded segment disclosures; however, it did not have a material impact. Accordingly, there were no material changes to our accounting policies during the three months ended March 31, 2025.
We regularly evaluate the accounting policies and estimates that we use to prepare our condensed consolidated financial statements. In general, management’s estimates are based on historical experience, information from third party professionals, and various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management under different and/or future circumstances.
Results of Operations – Comparison of Three-Month Periods Ended March 31, 2025 and 2024
Net sales to unrelated customers were $73,974 for the three months ended March 31, 2025, compared to $37,732 for the same period in 2024—an increase of $36,242, or approximately 96.05%. The increase was driven by higher private label customer order volumes and the timing of orders during the current quarter.
Net sales to a related party, Avini Health (Avini), were $36,420 for the three months ended March 31, 2025, compared to $34,949 for the same period in 2024—a slight increase of $1,471, or approximately 4.21%. Avini began manufacturing certain products in September 2023, and sales during the current quarter remained comparable to the prior-year period.
Cost of sales for the three–month period ended March 31, 2025 is $42,063 compared to $37,484 for the three–month period March 31, 2024. Our cost of sales includes the direct costs associated with manufacturing, shipping and handling costs. Our gross profit margin for the three–month period ended March 31, 2025 is $68,331 or 61.90% compared to $35,197 or 48.43% for the three–month period ended March 31, 2024. This gross margin includes reserves of $5,000 in the current quarter and $15,000 in the prior-year quarter for undelivered venom and slow-moving inventory, with a higher reserve recorded in the prior-year period. Excluding the reserve, gross margin for the current quarter (66.43%) would be comparable to the prior-year period (69.06%), with the modest variance primarily attributable to slightly higher manufacturing costs related to private label product sales to unrelated parties.
Selling, general and administrative expenses increased by $87,644, or 26.5%, from $330,506 for the quarter ended March 31, 2024 to $418,150 for the quarter ended March 31, 2025. The increase was primarily attributable to higher compensation expense related to officers appointed late in March 2024, which impacted a full quarter in the current period, as well as increased professional fees associated with the Company’s resumption of SEC filing activities.
Other income was $50,000 and $300 for the three months ended March 31, 2025 and 2024, respectively. A portion of other income relates to the amortization of debt discounts on convertible notes receivable, which totaled $0 and $300 for the three months ended March 31, 2025 and 2024, respectively. The $50,000 recognized during the current quarter of 2025 was attributable to income earned under a short-term research and development services contract.
Interest expense, including related party interest expense, increased $11,190 or 12.92%, from $86,605 for the quarter ended March 31, 2024 to $97,795 for the quarter ended March 31, 2025. This increase was primarily due to the increase in amortization of loan discounts in the quarter ended March 31, 2025 compared to the quarter ended March 31, 2024.
We carry certain of our debentures at fair value. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debt is included in the value of the derivative liabilities. For the three months ended March 31, 2025 and 2024, the liability related to these hybrid instruments fluctuated, resulting in a loss of $1,007,309 and $66,740, respectively. Interest expense on these debentures is included in the fair value loss in the accompanying unaudited condensed consolidated statements of operations.
Gain on settlement of debts for the three months ended March 31, 2024 is $21,420 compared to no gain or loss for the three months ended March 31, 2025, reflecting one debt settlement executed during the prior quarter.
As a result of the foregoing, our net loss increased by $977,989 or 229.07%, from net loss of $426,934 for the quarter ended March 31, 2024 to a net loss of $1,404,923 for the quarter ended March 31, 2025.
| 7 |
Liquidity and Capital Resources
We have incurred significant losses from operations and working capital and stockholders’ deficits raise substantial doubt about our ability to continue as a going concern. Further, as stated in Note 1 to our condensed consolidated unaudited financial statements for the period ended March 31, 2025, we have an accumulated deficit of $77,636,060 at March 31, 2025. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $16,296,563 and a stockholders’ deficit of $16,212,837 at March 31, 2025.
Our ability to continue as a going concern is contingent upon our ability to secure additional financing, increase ownership equity, and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern. In addition, our common stock is presently on the OTC Market Group’s Expert Market, which means that the Company’s common stock is not eligible for proprietary broker-deal quotes.
Current operations are primarily being funded through a combination of product sales, promissory notes and convertible notes. During the three months ended March 31, 2025, we raised $423,556 through the issuance of convertible notes.
We expect to utilize the proceeds from these funds and additional capital to manufacture Nyloxin and Pet Pain–Away and reduce our debt level. We estimate that we will require approximately $1,200,000 to fund our existing operations over the next twelve months. These costs include: (i) compensation for six (6) full-time employees; (ii) compensation for various consultants who we deem critical to our business; (iii) general office expenses including rent and utilities; (iv) product liability insurance; and (v) outside legal and accounting services. These costs reflected in (i) – (v) do not include research and development costs or other costs associated with clinical studies.
Our ability to meet our future operating expenses is highly dependent on the amount of such future revenues. To the extent that future revenues from the sales of Nyloxin and Pet Pain-Away are insufficient to cover our operating expenses we may need to raise additional equity capital, which could result in substantial dilution to existing shareholders. There can be no assurance that we will be able to raise sufficient equity capital to fund our working capital requirements on terms acceptable to us, or at all. We may also seek additional loans from our officers and directors; however, there can be no assurance that we will be successful in securing such additional loans.
The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Uncertainties and Trends
Our operations and possible revenues are dependent now and in the future upon the following factors:
| ● | Whether we successfully develop and commercialize products from our research and development activities. | |
| ● | If we fail to compete effectively in the intensely competitive biotechnology area, our operations and market position will be negatively impacted. | |
| ● | If we fail to successfully execute our planned partnering and out-licensing of products or technologies, our future performance will be adversely affected. | |
| ● | The recent economic downturn and related credit and financial market crisis may adversely affect our ability to obtain financing, conduct our operations and realize opportunities to successfully bring our technologies to market. | |
| ● | Biotechnology industry related litigation is substantial and may continue to rise, leading to greater costs and unpredictable litigation. | |
| ● | The decline in sales to Avini, as Avini has begun manufacturing its own products. This shift is expected to reduce our revenues going forward and may require us to develop new customer relationships or product lines to offset the reduction. | |
| ● | If we fail to comply with extensive legal/regulatory requirements affecting the healthcare industry, we will face increased costs, and possibly penalties and business losses. |
| 8 |
Off–Balance Sheet Arrangements
We have not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated with us under whom we have:
| ● | An obligation under a guarantee contract. | |
| ● | A retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets. | |
| ● | Any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument. | |
| ● | Any obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by us and material to us where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with us. |
We do not have any off-balance sheet arrangements or commitments that have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material, other than those which may be disclosed in this Management’s Discussion and Analysis of Financial Condition and the audited Consolidated Financial Statements and related notes.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable
Item 4. Controls and Procedures
Disclosure Controls and Procedures
As of March 31, 2025, we carried out an evaluation under the supervision and the participation of our Chief Executive Officer, of the effectiveness of our disclosure controls and procedures as of March 31, 2025, as defined in Rule 13a–15 under the Securities Exchange Act of 1934 (“Exchange Act”). Based on that evaluation, our management, including our Chief Executive Officer, concluded that, because of the material weaknesses in internal control over financial reporting discussed in Section 9A of our annual report on Form 10–K, our disclosure controls and procedures were not effective, at a reasonable assurance level, as of March 31, 2025. In light of this, we performed additional post–closing procedures and analyses in order to prepare the Condensed Consolidated Unaudited Financial Statements included in this report. As a result of these procedures, we believe our Condensed Consolidated Unaudited Financial Statements included in this report present fairly, in all material respects, our financial condition, results of operations and cash flows for the periods presented. A control system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the company have been detected.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer, who also acted as our Principal Financial Officer as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a–15 or 15d–15 under the Exchange Act that occurred during the quarter ended March 31, 2025 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| 9 |
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Marc Weller v. Nutra Pharma Corporation, Case No. CACE-24-018346
In January 2026, the Company entered into a settlement agreement with Marc Weller resolving litigation in Broward County, Florida. Pursuant to the settlement, the Company agreed to cancel and extinguish outstanding notes with an aggregate carrying value of approximately $175,000 in exchange for $20,000 in cash (payable in installments through April 2026) and the issuance of 60 million shares of common stock.
CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150
On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note. Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL, however, the mediation was unsuccessful. Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. On May 19, 2025, the Company entered into a settlement agreement with the counterparty, under which the total obligation was resolved for $125,000. The settlement terms include an initial payment of $35,000 made on May 19, 2025, followed by nine monthly payments of $10,000 each. The agreement also provides that, in the event of a payment default not cured within five business days of written notice, the counterparty may seek entry of a consent judgment against the Company in the amount of $400,000, reduced by any amounts already paid under the settlement. The total liability recorded prior to the settlement on May 19, 2025 was $178,526, consisting of $91,156 in principal and $87,370 in accrued interest. The settlement of $125,000 will result in a gain on settlement of $53,526, which will be recognized upon full satisfaction of the payment terms.
Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus
On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws.
The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief.
| 10 |
On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On June 30, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021.
In July 2024, a final judgment was issued, ordering the defendant to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty. As of March 31, 2025 and December 31, 2024, the Company had accrued a total legal settlement amount of $680,235.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
There were no unregistered sales of equity securities.
Item 3. Defaults Upon Senior Securities
As of March 31, 2025, certain of the Company’s promissory notes and convertible promissory notes were in default. The Company is currently negotiating settlements with the respective noteholders. Additional information regarding these notes is included in Note 6 – Debt Notes to the condensed consolidated financial statements included in Part I of this report.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None
Item 6. Exhibits
| Exhibit No. | Title | |
| 31.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes–Oxley Act of 2002. | |
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes–Oxley Act of 2002. | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 11 |
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NUTRA PHARMA CORP. | ||
| Registrant | ||
| Dated: March 11, 2026 | /s/ Michael Flax, DDS | |
| Michael Flax, DDS | ||
| Chief Executive Officer/Chief Financial Officer |
| 12 |
FAQ
How did Nutra Pharma Corp. (NPHC) perform financially in the quarter ended March 31, 2025?
What is Nutra Pharma Corp.’s (NPHC) liquidity position and cash balance as of March 31, 2025?
Why has Nutra Pharma Corp. (NPHC) raised substantial going concern doubts?
How much debt does Nutra Pharma Corp. (NPHC) have outstanding, and what are the key features?
What legal and regulatory liabilities affect Nutra Pharma Corp. (NPHC)?
How reliant is Nutra Pharma Corp. (NPHC) on related-party sales and arrangements?
